Somavert (PEGvisomant) Patent Expiration, LOE Window & CMS Spending

Somavert (PEGvisomant) by Pfizer: Biologic BLA (Purple Book Regime), 0 AB generics, $48.0M 2024 CMS Part D & Medicaid spend, and 25 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorPfizer
FDA Application & PathwayB021106 (BLA)
Exclusivity / Cliff HorizonBiologic BLA (Purple Book Regime)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$48.0M
2024 Medicare Part D Spend$37.3M
2024 Medicaid Spend$10.7M
Reported Wholesale Price Change (CA SB 17)25 WAC filings (max 22.3% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.